Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is May 23, 2025, covering a share repurchase executed on May 22, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics and Transaction Details
- Shares Purchased: 547,990 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,417.00 GBp; highest price paid was 1,440.50 GBp.
- Average Price: Volume-weighted average price paid was 1,426.64 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Shares: Following this purchase, GSK holds 214,495,913 ordinary shares in treasury.
- Shares in Issue: 4,100,762,946 ordinary shares (excluding treasury shares).
- Voting Rights: Total voting rights stand at 4,100,762,946.
Material Changes and Programme Progress
Since the commencement of the current buyback agreement on February 24, 2025, GSK has purchased an aggregate of 45,425,610 ordinary shares. The filing does not provide comparative financial data (revenue, profit, cash flow) for the period, as the document is strictly a disclosure of share repurchase activity.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Investors are directed to the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and the Q1 Results for 2025 for detailed risk disclosures. No new guidance or management commentary regarding operational outlook is provided in this specific filing.
Investor Verification Checklist
- Verify the total number of treasury shares held (214,495,913) against the latest Form 20-F or quarterly reports to confirm the impact on earnings per share.
- Confirm the remaining capacity under the buyback programme authorized on February 24, 2025.
- Review the "Risk Factors" in the 2024 Form 20-F and 2025 Q1 results as referenced in the cautionary statement.
- Check the total voting rights denominator (4,100,762,946) for compliance with FCA Disclosure Guidance and Transparency Rules.